Effect of magnetic resonance exposure combined with gadopentetate dimeglumine on chromosomes in animal specimens

Rofsky, Neil M.; Pizzarello, Donald J.; Duhaney, Michael; Falick, Amanda K.; Prendergast, Nancy C.; Weinreb, Jeffrey C.

doi:10.1016/s1076-6332(05)80405-2

Cited by 18 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In rats, neither exposure to gadopentetate dimeglumine plus magnetic resonance nor exposure to gadopentetate dimeglumine alone caused anaphase bridge formation, an indicator of chromosome damage [17]. Neither intraperitoneal gadopentetate dimeglumine plus magnetic resonance nor intraperitoneal gadopentetate dimeglumine alone had any detectable effect on the development of mice [18].…”

Section: Mutagenicity and Teratogenicity Of Contrast Mediamentioning

confidence: 89%

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Webb

Thomsen

Morcos³

2004

Eur Radiol

512

180

View full text Add to dashboard Cite

The use of iodinated or gadolinium-based contrast media in pregnant or lactating women often causes concerns in the radiology department because of the principle of not exposing a fetus or neonate to any drugs. Because of the uncertainty about the use of contrast media during pregnancy and lactation, the Contrast Media Safety Committee of the European Society of Urogenital Radiology decided to review the literature and draw up guidelines. An extensive literature search was carried out and summarized in a report. Based on the limited information available, simple guidelines have been drawn up. The report and guidelines were discussed at the 11th European Symposium on Urogenital Radiology in Santiago de Compostela, Spain. Mutagenic and teratogenic effects have not been described after administration of gadolinium or iodinated contrast media. Free iodide in radiographic contrast medium given to the mother has the potential to depress fetal/neonatal thyroid function. Neonatal thyroid function should be checked during the 1st week if iodinated contrast media have been given during pregnancy. No effect on the fetus has been seen after gadolinium contrast media. Only tiny amounts of iodinated or gadolinium-based contrast medium given to a lactating mother reach the milk, and only a minute proportion entering the baby's gut is absorbed. The very small potential risk associated with absorption of contrast medium may be considered insufficient to warrant stopping breast-feeding for 24 h following either iodinated or gadolinium contrast agents.

show abstract

Section: Mutagenicity and Teratogenicity Of Contrast Mediamentioning

confidence: 89%

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Webb

Thomsen

Morcos³

2004

Eur Radiol

512

180

View full text Add to dashboard Cite

show abstract

“…Safety data on gadolinium use in pregnancy are inconsistent. Several animal studies revealed growth retardation and higher rates of congenital malformations, though the dose of gadolinium was two to seven times higher than usual doses in human studies, in contrast this disadvantage was not seen in other animal studies . Beyond animal studies, there are only few data on the use of gadolinium in pregnant women.…”

Section: Pregnancymentioning

confidence: 99%

Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation

Schulze

Esters

Dignaß

2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Animal studies performed with all of the approved agents have demonstrated diverse, and in some cases severe, adverse effects, but only with markedly increased doses and/or extensive periods of exposure (7,71,(75)(76)(77)(78)(79)(80). Based on these findings, there is legitimate concern about the in utero effects of prolonged exposure to highdose intravenous Gd chelates; however, the more relevant question of exposure to a single clinical dose in humans remains open.…”

Section: Pregnancymentioning

confidence: 99%

MR contrast agents: Physical and pharmacologic basics

Lin

Brown

2007

Magnetic Resonance Imaging

224

175

View full text Add to dashboard Cite

Since approval of the first magnetic resonance (MR) contrast agent was granted in 1988, there has been remarkable growth in the utilization of intravenous gadolinium (Gd)-based agents. Currently it is estimated that nearly half of all MR studies performed are contrast-enhanced. Despite containing a toxic heavy metal, these agents have proven to be not only an effective diagnostic adjunct to non-enhanced MRI, but also remarkably well tolerated and safe. As a result, conventional wisdom has been that MR contrast media are "biologically inert," a notion that is clearly false. Ultimately, it is the radiologist's responsibility to understand the potential adverse effects of Gd-based agents and the special situations in which they are likely to occur; however, the basic pharmacology of contrast agents is generally not included in medical school curricula or formally taught in residency. The purpose of this review is to discuss the mechanism of action of MR contrast agents and relevant aspects of their clinical pharmacology, including effects on the cardiovascular and renal systems, potential laboratory errors, and special situations involving women and children. We also briefly discuss the issue of nephrogenic systemic fibrosis (NSF).

show abstract

Effect of magnetic resonance exposure combined with gadopentetate dimeglumine on chromosomes in animal specimens

Cited by 18 publications

References 16 publications

The use of iodinated and gadolinium contrast media during pregnancy and lactation

The use of iodinated and gadolinium contrast media during pregnancy and lactation

Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation

MR contrast agents: Physical and pharmacologic basics

Contact Info

Product

Resources

About